NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.
Discovering drugs that create neoantigens
DNA Mismatch Repair Inhibitors
Clinicians see excellent immune responses for certain cancers that lack the mismatch repair ('MMR') genes targeted by NeoPhore’s approach
| Status | Active |
| Website | https://www.neophore.com/ |
| Category | Biotech |
| Modality | Small Molecule |
| Therapeutics Area | Oncology |
| Headquaters | Cambridge, UK |
| Partner | Phoremost |
| Investment Portfolio | Pre-Fund Investment |
| Co-Investors | Parkwalk Sixth Element |